Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues
- PMID: 17632455
- DOI: 10.1038/modpathol.3800903
Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues
Abstract
Recurrent gene fusions between TMPRSS2 and ETS family genes have recently been shown to occur at a high frequency in prostate cancer. In this study, we used formalin-fixed paraffin-embedded tissue and evaluated both TMPRSS2-ERG and TMPRSS2-ETV1 fusions by reverse transcription polymerase chain reaction (RT-PCR) and fluorescence in situ hybridization (FISH). The results were correlated to overexpression of the downstream ERG and ETV1 sequences. Of 82 cases examined, TMPRSS2-ETV1 fusion was seen in only one case, by FISH. In comparison, TMPRSS2-ERG fusion was documented in 35 cases (43%) by either RT-PCR or FISH. Deletion, rather than translocation, was found to be the main mechanism for TMPRSS2-ERG gene fusion (81 vs 19%). RT-PCR and FISH results correlated well, with most positive cases resulting in overexpression of downstream ERG sequences. Several TMPRSS2-ERG fusion transcript variants were identified, most of which are predicted to encode truncated ERG proteins. Prostate cancer of Gleason's scores 6 or 7 had more frequent TMPRSS2-ERG fusions than higher-grade tumors, but this difference was not statistically significant (P=0.42). On the other hand, mucin-positive carcinomas more often harbor such gene fusions when compared to mucin-negative tumors (P=0.004). These morphological correlates, and more importantly the potential correlation of such fusions to clinical outcome and treatment responses, should be further explored.
Similar articles
-
ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.Mod Pathol. 2010 Nov;23(11):1492-8. doi: 10.1038/modpathol.2010.149. Epub 2010 Aug 6. Mod Pathol. 2010. PMID: 20693979
-
TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.Asian Pac J Cancer Prev. 2014;15(7):3099-103. doi: 10.7314/apjcp.2014.15.7.3099. Asian Pac J Cancer Prev. 2014. PMID: 24815454
-
TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.Cancer Res. 2006 Nov 15;66(22):10658-63. doi: 10.1158/0008-5472.CAN-06-1871. Cancer Res. 2006. PMID: 17108102
-
[The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer].Yi Chuan. 2011 Feb;33(2):117-22. doi: 10.3724/sp.j.1005.2011.00117. Yi Chuan. 2011. PMID: 21377967 Review. Chinese.
-
Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management.Adv Anat Pathol. 2013 Mar;20(2):117-24. doi: 10.1097/PAP.0b013e3182862ac5. Adv Anat Pathol. 2013. PMID: 23399797 Review.
Cited by
-
Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models.Mol Carcinog. 2022 Jul;61(7):717-734. doi: 10.1002/mc.23413. Epub 2022 Apr 22. Mol Carcinog. 2022. PMID: 35452553 Free PMC article.
-
The Genomics of Prostate Cancer: A Historic Perspective.Cold Spring Harb Perspect Med. 2019 Mar 1;9(3):a034942. doi: 10.1101/cshperspect.a034942. Cold Spring Harb Perspect Med. 2019. PMID: 29712681 Free PMC article. Review.
-
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.Nat Genet. 2009 May;41(5):619-24. doi: 10.1038/ng.370. Epub 2009 Apr 26. Nat Genet. 2009. PMID: 19396168 Free PMC article.
-
Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status.Hum Mol Genet. 2016 Dec 15;25(24):5490-5499. doi: 10.1093/hmg/ddw349. Hum Mol Genet. 2016. PMID: 27798103 Free PMC article.
-
Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas.Mod Pathol. 2011 Nov;24(11):1511-20. doi: 10.1038/modpathol.2011.111. Epub 2011 Jul 8. Mod Pathol. 2011. PMID: 21743434 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical